Serum levels of sTNFR-1 and sFas in patients with relapsing-remitting multiple sclerosis

Medical Science Monitor

Volumn 8, Issue 10, 2002, Pages

  Bilińska, Małgorzata ^a   Frydecka, Irena ^a   Podemski, Ryszard ^a   Gruszka, Ewa ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Multiple sclerosis; Serum; Soluble Fas receptor; Soluble TNF 1 receptor

Indexed keywords

FAS ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; MEASUREMENT; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; PROTEIN BINDING; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; T LYMPHOCYTE ACTIVATION; ADOLESCENT; BLOOD; MIDDLE AGED; PATHOPHYSIOLOGY; STATISTICS;

ADOLESCENT; ADULT; ANTIGENS, CD95; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; STATISTICS;

EID: 1842834294     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Raine CS: The Dale E, McFarlin memorial lecture: The immunology of multiple sclerosis. Ann Neurol, 1994; 36: 61-72
2. Carlos TM, Harlan JM: Leukocyte-endothelial adhesion molecules. Blood, 1994; 84: 2068-2101
3. Zhang J, Markovic-Plese S, Lacet B et al: Increased frequency of interleukin-2 responsive and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med, 1994; 179: 973-984
4. Bieganowska KD, Ausubel LJ, Modabber Y et al: Direct in vivo analysis of activated Fas-sensitive autoreactive T cells in human autoimmunne disease. J Exp Med, 1997; 185: 1585-1594
5. Mena E, Rochovsky-Kochan C: Expression of costimulatory molecules in peripheral blood mononuclear cells in multiple sclerosis. Acta Neurol Scand, 1999; 100: 92-96
6. Hurwitz AA, Sullivan TJ, Krummel MF et al: Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histological disease in an actively-induced model of experomental allergic encephalomyelitis. J Neuroimmunol, 1997; 73: 57-62
7. Ligers A, Xu C, Saarinen S et al: The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol, 1999; 97: 182-190
8. Sharief MK, Noori MA, Ciardi M et al: Increased levels of circulat ing ICAM-1 in serum and cerebrospinal fluid of patients with multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier. J Neuroimmunol, 1993; 43: 15-22
9. Wong D, Dorovini-Zis K: Upregulation ofintracellular adhesion molecule -1 (ICAM-1) expression of primary cultures of human brain microvessel endothelial cells by cytokine and lipopolisaccharide. J Neuroimmunol, 1992; 39: 11-18
10. Tartaglia LA, Goeddel DV: Two TNF receptors. Immunology Today, 1992; 13: 151-153
11. Leeuwenberg JFM, Jeunhomme TMAA, Buurman WA: Slow release of soluble TNF receptors by monocytes in vitro. J Immunol, 1994; 152: 4036-4043
12. Riecmann P, Martin S, Weichselbraun I, Albrecht M et al: Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: c1CAM-1 is an indicator of relapse. Neurology, 1994; 44: 2367-2373
13. Owen-Schaub LB, Yonehara S, Crump II WL: DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by sFas antigen engagement. Cell Immunology, 1992; 140: 197-205
14. Wesselborg S, Janssen O, Kabelitz D: Induction of activation-driven death (apoptosis) in activated but non resting peripheral blood T cells. J Immunol, 1993; 150: 4338-4349
15. Suda T, Nagata S: Purification and characterization of Fas-ligand that induced apoptosis. J Exp Med, 1994; 179: 873-879
16. Nagata S, Goldstein P: The Fas death factor. Science, 1995; 267: 1449-1456
17. Dhein J, Walczak H, Baumler C et al: Autocrine T-cell suicide mediated by Apo-1 (Fas/CD95). Nature, 1995; 373: 438-441
18. Brunner T, Mogil RJ, LaFace D et al: Cell-autonomous Fas (CD95) Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature, 1995; 373: 441-444
19. Cheng J, Zhou T, Liu CH et al: Protection from fas-mediated apoptosis by soluble form of Fas molecule. Science, 1994; 263: 1759-1762
20. Lublin FD, Reigold SC: Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology, 1996; 46: 907-911
21. Poser CHM: New diagnostic criteria for multiple sclerosis guidelines for research protocols. Ann Neurol, 1983; 13: 227-234
22. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 1983; 33: 1444-1452
23. Hartung H-P, Reiners K, Archelos JJ et al: Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: Correlation with magnetic resonance imaging. Ann Neurol, 1995; 38: 186-193
24. Selmaj K, Papierz W, Glabiński A, Kohno T: Prevention of chronic relapsing experimental autoimmune encephapolyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol, 1995; 56: 135-141
25. Spuler S, Yousry T, Scheller A et al: Multiple sclerosis: Prospective analysis of TNF-alpha and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. J Neuroimmunol, 1996; 66: 57-64
26. Ichikawa H, Ota K, Iwata M: Increased Fas antigen on T cells in multiple sclerosis. J Neuroimmunol, 1996; 71: 125-129
27. Zipp F, Faber E, Sommer N et al: CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis. No difference from normal individuals and no relations to HLA-DR2. J Neuroimmunol, 1998; 81: 168-172
28. Inoue A, Koh CH-S, Sakai T et al: Detection of soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type -I associated myelopathy. J Neuroimmunol, 1997; 75: 141-146
29. Ciusani E, Frigerio S, Gelati M et al: Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol, 1998; 82: 5-12
30. Zipp F, Weller M, Calabresi Correspondence address: et al: Increased serum levels of soluble CD95 (Apo-1, Fas) in relapsing-remitting multiple sclerosis. Ann Neurol, 1998; 43: 116-120
31. Papoff G, Cascino I, Eramo A et al: An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol, 1996; 156: 4622-4630
32. Zipp F, Otzelberger K, Dichgand J et al: Serum CD95 of relapsing-remitting multiple sclerosis patients protects from CD95-mediated apoptosis. J Neuroinmmnol, 1998; 86: 151-154